HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

THE EFFECTS OF BIOREGULATORY DRUGS ON INFLAMMATION MARKERS AND QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE CONCURRENT WITH CORONARY HEART DISEASE

DOI: https://doi.org/10.29296/25877305-2018-02-08
Download full text PDF
Issue: 
2
Year: 
2018

L. Dolinina, Candidate of Medical Sciences I.I. Mechnikov North-Western State Medical University, Saint Petersburg

The paper presents the results of investigating the efficacy of bioregulatory drugs in the combination treatment of patients with varying severity of chronic obstructive pulmonary disease (COPD) concurrent with coronary heart disease (CHD). Estimation of inflammation markers in sputum, bronchial lavages, and serum, such as interleukin (IL)-8, tumor necrosis factor-α, interferon-γ, IL-10, and C-reactive protein before and after treatment revealed the good anti-inflammatory effect of the bioregulatory drugs. Their incorporation into conventional treatment regimens for COPD and CHD can enhance the efficiency of treatment and improve quality of life in patients.

Keywords: 
pulmonology
cardiology
chronic obstructive pulmonary disease
coronary heart disease
inflammation
quality of life
bioregulatory drugs



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Global'naja strategija diagnostiki, lechenija i profilaktiki hronicheskoj obstruktivnoj bolezni legkih (Peresmotr 2014 g.). Per. s angl. / M.: Rossijskoe respiratornoe obschestvo, 2014; 92 s.
  2. Avdeev S.N., Bajkamakanova G.E. Strategija vedenija kardiologicheskogo patsienta, stradajuschego HOBL. Kardiopul'monologicheskie vzamiootnoshenija // Serdtse. – 2007; 6 (6): 305–9.
  3. Avdeev S.N., Bajmakanova G.E. HOBL i serdechno-sosudistye zabolevanija: mehanizmy assotsiatsii // Pul'monologija. – 2008; 1: 5–13.
  4. Brodskaja T.A., Nevzorova V.A., Gel'tser B.I. i dr. Disfunktsija endotelija i bolezni organov dyhanija // Ter. arh. – 2007; 3: 76–84.
  5. Karoli N.A. Hronicheskaja obstruktivnaja bolezn' legkih i kardiovaskuljarnaja patologija: kliniko-funktsional'nye vzaimootnoshenija i prognozirovanie techenija. Avtoref. dis. … d-ra med. nauk. Saratov, 2007; 46 s.
  6. Huiart L., Ernst R., Suissa S. Cardiovascular morbidity and mortality in COPD // Chest. – 2005; 128 (4): 2640–6.
  7. Hurst J., Donaldson G., Perera W. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease // Am. J. Respir. Crit. Care Med. – 2006; 174: 867–74.
  8. Hurst J., Perera W., Wilkinson T. et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease // Am. J. Respir. Crit. Care Med. – 2006; 173: 71–8.
  9. Hurst J., Vestbo A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease // N. Engl. J. Med. – 2010; 363: 1128–38.
  10. Sin D., Man S. Chronic obstruc- tive pulmonary disease as a risk factor for cardiovascular morbidity and mortality // Proc. Am. Thorac. Soc. – 2005; 2: 8–11.
  11. Sin D., Anthonisen N., Soriano J. et al. Mortality in COPD: role of comorbidities // Eur. Respir. J. – 2006; 28: 1245–57.
  12. Delieva A.N. Rol' aktivnosti vospalenija v bronhah i na sistemnom urovne v patogeneze HOBL, a takzhe pri sochetanii HOBL i IBS. Avtoref. dis. ... kand. med. nauk. SPb, 2015; 22 s.